NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 137 filers reported holding NEKTAR THERAPEUTICS in Q3 2023. The put-call ratio across all filers is 5.78 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $426,525 | +2.1% | 716,126 | -1.4% | 0.00% | – |
| Q2 2023 | $417,559 | -91.5% | 725,937 | -89.6% | 0.00% | – |
| Q1 2023 | $4,907,007 | -85.2% | 6,981,089 | -52.4% | 0.00% | -100.0% |
| Q4 2022 | $33,156,854 | +31.9% | 14,671,174 | +86.7% | 0.00% | -50.0% |
| Q3 2022 | $25,142,000 | -24.2% | 7,856,892 | -10.0% | 0.00% | 0.0% |
| Q2 2022 | $33,170,000 | +6.1% | 8,728,968 | +50.5% | 0.00% | 0.0% |
| Q1 2022 | $31,264,000 | -56.3% | 5,800,302 | +9.6% | 0.00% | -33.3% |
| Q4 2021 | $71,489,000 | -14.4% | 5,291,548 | +13.8% | 0.00% | -25.0% |
| Q3 2021 | $83,498,000 | +2.5% | 4,649,113 | -2.1% | 0.00% | 0.0% |
| Q2 2021 | $81,468,000 | -7.0% | 4,747,581 | +8.4% | 0.00% | -20.0% |
| Q1 2021 | $87,572,000 | +15.1% | 4,378,595 | -2.2% | 0.01% | 0.0% |
| Q4 2020 | $76,085,000 | +7.9% | 4,475,576 | +5.3% | 0.01% | 0.0% |
| Q3 2020 | $70,510,000 | -31.8% | 4,250,121 | -4.8% | 0.01% | -37.5% |
| Q2 2020 | $103,401,000 | +25.1% | 4,464,647 | -3.6% | 0.01% | +14.3% |
| Q1 2020 | $82,673,000 | -15.8% | 4,631,555 | +1.8% | 0.01% | 0.0% |
| Q4 2019 | $98,214,000 | -27.3% | 4,550,105 | -38.7% | 0.01% | -30.0% |
| Q3 2019 | $135,146,000 | -46.8% | 7,419,493 | +3.9% | 0.01% | -47.4% |
| Q2 2019 | $254,131,000 | +6.5% | 7,142,510 | +0.6% | 0.02% | 0.0% |
| Q1 2019 | $238,523,000 | +6.9% | 7,098,904 | +4.5% | 0.02% | -5.0% |
| Q4 2018 | $223,201,000 | -44.6% | 6,790,432 | +2.7% | 0.02% | -35.5% |
| Q3 2018 | $403,099,000 | +37.5% | 6,612,531 | +10.1% | 0.03% | +24.0% |
| Q2 2018 | $293,175,000 | -56.4% | 6,003,908 | -5.1% | 0.02% | -56.1% |
| Q1 2018 | $672,266,000 | +182.9% | 6,326,603 | +59.0% | 0.06% | +200.0% |
| Q4 2017 | $237,620,000 | +149.5% | 3,978,809 | +0.3% | 0.02% | +137.5% |
| Q3 2017 | $95,246,000 | +10.5% | 3,968,428 | -10.0% | 0.01% | 0.0% |
| Q2 2017 | $86,179,000 | -7.3% | 4,408,270 | +11.3% | 0.01% | 0.0% |
| Q1 2017 | $92,967,000 | +86.5% | 3,961,247 | -2.5% | 0.01% | +60.0% |
| Q4 2016 | $49,839,000 | -12.9% | 4,062,468 | +21.9% | 0.01% | -16.7% |
| Q3 2016 | $57,237,000 | +23.0% | 3,331,632 | +1.9% | 0.01% | +20.0% |
| Q2 2016 | $46,535,000 | -2.8% | 3,270,484 | -6.0% | 0.01% | 0.0% |
| Q1 2016 | $47,852,000 | -14.7% | 3,480,120 | +4.5% | 0.01% | -16.7% |
| Q4 2015 | $56,093,000 | +8.5% | 3,328,749 | -29.5% | 0.01% | 0.0% |
| Q3 2015 | $51,719,000 | -23.6% | 4,719,006 | -12.7% | 0.01% | -14.3% |
| Q2 2015 | $67,661,000 | +27.9% | 5,408,175 | +12.5% | 0.01% | +40.0% |
| Q1 2015 | $52,905,000 | -17.1% | 4,809,266 | +16.8% | 0.01% | -16.7% |
| Q4 2014 | $63,845,000 | +27.1% | 4,118,758 | -1.1% | 0.01% | +20.0% |
| Q3 2014 | $50,246,000 | -16.3% | 4,163,202 | -11.1% | 0.01% | -16.7% |
| Q2 2014 | $60,017,000 | +18.1% | 4,681,405 | +11.6% | 0.01% | 0.0% |
| Q1 2014 | $50,825,000 | -29.3% | 4,193,432 | -43.4% | 0.01% | +20.0% |
| Q4 2013 | $71,849,000 | +104.5% | 7,406,965 | +120.3% | 0.01% | +25.0% |
| Q3 2013 | $35,128,000 | -0.8% | 3,361,786 | +9.7% | 0.00% | -20.0% |
| Q2 2013 | $35,395,000 | – | 3,064,246 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Rhenman & Partners Asset Management AB | 508,000 | $6,132,000 | 1.80% |
| Bodri Capital Management, LLC | 250,000 | $3,018,000 | 1.46% |
| Granahan Investment Management | 3,442,980 | $41,557,000 | 1.28% |
| TIRSCHWELL & LOEWY INC | 603,441 | $7,284,000 | 1.22% |
| NEA Management Company, LLC | 1,825,600 | $22,035,000 | 1.12% |
| Cormorant Asset Management, LP | 450,000 | $5,432,000 | 1.12% |
| HARVEY CAPITAL MANAGEMENT INC | 221,750 | $2,676,000 | 1.05% |
| Cheyne Capital Management (UK) LLP | 229,577 | $2,772,000 | 0.99% |
| Artal Group S.A. | 1,650,000 | $19,916,000 | 0.73% |
| FIC CAPITAL INC | 147,293 | $1,778,000 | 0.71% |